Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals Stock?Zacks Investment Research • 10/14/25
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth ProfileBusiness Wire • 10/14/25
Down 14.3% in 4 Weeks, Here's Why BioCryst (BCRX) Looks Ripe for a TurnaroundZacks Investment Research • 10/07/25
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Cantor Global Healthcare Conference 2025 TranscriptSeeking Alpha • 09/05/25
BioCryst Pharmaceuticals (BCRX) Surpasses Q2 Earnings and Revenue EstimatesZacks Investment Research • 08/04/25
BioCryst Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 08/04/25
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the StockZacks Investment Research • 07/31/25
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in DecemberGlobeNewsWire • 07/31/25
BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research • 07/28/25
BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National SummitGlobeNewsWire • 07/09/25
Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 07/07/25
BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate DevelopmentGlobeNewsWire • 07/07/25
BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 MillionGlobeNewsWire • 06/27/25
BioCryst (BCRX) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks Investment Research • 06/25/25
5 Must-Buy Efficient Stocks to Buy for Solid Gains Amid VolatilityZacks Investment Research • 06/25/25
BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACIGlobeNewsWire • 06/16/25
BioCryst Achieves Reimbursement for ORLADEYO Across all Major European CountriesGlobeNewsWire • 06/06/25